Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.
from USATODAY - News Top Stories https://ift.tt/69s8xtB
via IFTTT
Trial data showed the new vaccine, developed by GlaxoSmithKline, was 82% effective at preventing lower respiratory tract illness caused by RSV.
0 comments:
Post a Comment